New class of anitbiotics reaches marketplace.(Focus) From: Chain Drug Review | Date: September 29, 2003 | COPYRIGHT 2003 Racher Press, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group.Copyright information

LEXINGTON, Mass. -- The first in a new class of antibiotics (cyclic lipopeptide agents) is reaching the market through the efforts of the biopharmaceutical industry.

Cubist Pharmaceuticals Inc. received Food and Drug Administration approval earlier this month for Cubicin (daptomycin for injections), a once-daily treatment that the biotech company asserts has been proven effective against methicillin-resistant staphylococcus aereus (MRSA) and methicillin-susceptible S. ae...